Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 155.47%.

  • bioAffinity Technologies' EBITDA Margin fell 732100.0% to 155.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 150.61%, marking a year-over-year decrease of 645300.0%. This contributed to the annual value of 93.9% for FY2024, which is 2117300.0% up from last year.
  • As of Q3 2025, bioAffinity Technologies' EBITDA Margin stood at 155.47%, which was down 732100.0% from 194.65% recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' EBITDA Margin registered a high of 79.22% during Q1 2024, and its lowest value of 166806.19% during Q1 2023.
  • For the 4-year period, bioAffinity Technologies' EBITDA Margin averaged around 27394.89%, with its median value being 175.06% (2025).
  • Per our database at Business Quant, bioAffinity Technologies' EBITDA Margin skyrocketed by 1667269700bps in 2024 and then tumbled by -1092600bps in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' EBITDA Margin stood at 68902.77% in 2022, then surged by 100bps to 98.32% in 2023, then plummeted by -34bps to 131.53% in 2024, then fell by -18bps to 155.47% in 2025.
  • Its last three reported values are 155.47% in Q3 2025, 194.65% for Q2 2025, and 139.37% during Q1 2025.